Login / Signup

Long-term assessment of haematological recovery following somatic genetic rescue in a MYSM1-deficient patient: Implications for in vivo gene therapy.

Sophie de TocquevilleEmmanuel MartinQuentin RillerLaëtitia KermassonBenoit FranceAude MagérusFrédéric Rieux-LaucatFrançois DelhommeauPierre HirschAurore TouzartAude EchalierAlain FischerDespina MoshousPatrick Revy
Published in: British journal of haematology (2024)
MYSM1 deficiency causes inherited bone marrow failure syndrome (IBMFS). We have previously identified an IBMFS patient with a homozygous pathogenic variant in MYSM1 who recovered from cytopenia due to spontaneous correction of one MYSM1 variant in the haematopoietic compartment, an event called somatic genetic rescue (SGR). The study of the genetic and biological aspects of the patient's haematopoietic/lymphopoietic system over a decade after SGR shows that one genetically corrected haematopoietic stem cell (HSC) can restore a healthy and stable haematopoietic system. This supports in vivo gene correction of HSCs as a promising treatment for IBMFS, including MYSM1 deficiency.
Keyphrases
  • copy number
  • case report
  • genome wide
  • stem cells
  • bone marrow
  • gene therapy
  • mesenchymal stem cells
  • dna methylation
  • genome wide analysis